Bal Pharma 2026 Postal Ballot: Warrant Price Raised

Introduction

Bal Pharma Limited has flagged a key change to its ongoing postal ballot process after issuing a corrigendum that revises the pricing of proposed convertible warrants. The company’s July 30, 2026 intimation gave shareholders a 48-hour period to submit comments, observations, or objections on the corrigendum, which is being treated as an integral part of the earlier postal ballot notice dated July 9, 2026. The change matters because the issue price directly affects the amount of capital the company can raise and the terms at which promoter-linked capital is proposed to enter the business. Investors tracking preferential issues typically look closely at price revisions, timelines, and voting mechanics. Bal Pharma has also clarified that shareholders can modify their votes through remote e-voting within the permitted window. The remote e-voting facility remains open until 5:00 P.M. IST on August 8, 2026.

What Bal Pharma informed shareholders on July 30

In its exchange intimation dated July 30, 2026, Bal Pharma said it is providing shareholders 48 hours to submit their views on a corrigendum linked to the postal ballot notice. The company asked for comments, observations, or objections, indicating a short, time-bound opportunity to react to the revised terms. This communication sits alongside the earlier postal ballot process that had already opened remote e-voting on July 10, 2026. Importantly, Bal Pharma also stated that shareholders can change or modify their votes through the remote e-voting platform. That flexibility is relevant when the underlying proposal changes after voting has started. The company’s update positions the corrigendum as part of the same approval process rather than a separate shareholder exercise.

The corrigendum: issue price revised to ₹84 from ₹81

Bal Pharma’s corrigendum is dated July 23, 2026 and revises the issue price of the proposed convertible warrants. The updated issue price is ₹84 per warrant, increased from ₹81 per warrant mentioned in the earlier proposal. With the revised price, the potential capital raise mentioned in the article rises to ₹8.4 crore. The company has linked the proceeds to an API plant in Karnataka, which is the stated end-use in the provided information. Since the number of warrants is 10,00,000, a price change of ₹3 per warrant is a material term change for a preferential issue. The earlier aggregation at ₹81 per warrant was cited as ₹8.10 crore, highlighting the magnitude of the revision.

Postal ballot mechanics and e-voting window

The remote e-voting process for the postal ballot runs from July 10, 2026 to August 08, 2026. Bal Pharma has specified the start time as 09:00 A.M. IST on July 10, 2026 and the end time as 5:00 P.M. IST on August 08, 2026. The company has also stated that the results of the postal ballot will be announced at the registered office on or before August 11, 2026. Such timelines are important for investors because they define when the terms of the fund-raising can become effective. The company’s July 30 communication reiterates that the e-voting facility remains open until the stated closing time on August 8. The cut-off date for determining eligibility to vote is July 03, 2026.

NSDL as the e-voting agency and the scrutinizer

Bal Pharma has engaged National Securities Depository Limited (NSDL) to facilitate remote e-voting. The company also appointed Mr. Parameshwar Bhat, Practicing Company Secretary, as the Scrutinizer to oversee the process. The scrutinizer’s role is to supervise voting, review the results, and provide a report in line with process requirements. Bal Pharma has outlined voting access routes depending on how shares are held. Shareholders holding shares in demat mode can vote through their depository participants or the NSDL e-Voting website. Shareholders holding physical shares must use the NSDL e-Voting system as described by the company.

The fund-raise proposal: 10,00,000 warrants to promoter

The postal ballot seeks shareholder approval for a preferential issue of 10,00,000 warrants to a promoter. The article notes that the proposal involves allotment to promoter Mr. Shailesh Siroya. In the earlier pricing, the company described the issue at ₹81 per warrant, aggregating to ₹8.10 crore. The corrigendum revises the price to ₹84, and the article states the potential capital raise increases to ₹8.4 crore. Bal Pharma’s disclosure also notes that the board approved the preferential issue of warrants to promoters and decided to seek shareholder approval for this fund-raising exercise through a postal ballot. This sequence matters because it places the proposal within the standard path of board approval followed by shareholder approval.

How the corrigendum affects votes already cast

Bal Pharma has explicitly stated that shareholders can modify their votes via remote e-voting. That point becomes relevant because a price revision can change how shareholders evaluate a preferential issue. The company’s 48-hour comment window on the corrigendum is positioned as an additional opportunity to record views. While the e-voting process remains open until August 8, the company’s July 30 update highlights the narrow time window for submitting comments on the corrigendum itself. For shareholders who already voted earlier in the window, the ability to revise a vote ensures the final tally reflects the latest terms. The outcome will ultimately be reflected in the postal ballot results expected on or before August 11, 2026.

Key facts at a glance

Background: earlier 2026 postal ballot and voting outcome

Bal Pharma’s disclosures also include details of a separate postal ballot process earlier in 2026 related to board composition. The company initiated a postal ballot for shareholder approval of Dr. Mukesh Beekamchand’s appointment as Independent Director for a five-year term. That e-voting period ran from January 9 to February 7, 2026, with results expected by February 10. Bal Pharma later informed that the ordinary resolution for the appointment was passed with the requisite majority. The process was also facilitated by NSDL, and Mr. Parameshwar Bhat was appointed as Scrutinizer for that postal ballot as well. The voting analysis provided shows a high level of support for the resolution based on votes cast.

Market context: current share price cited

The article text also mentions a market datapoint, stating the current price of Bal Pharma Ltd is ₹89.23. While the postal ballot process is a governance and capital-raising event, market participants often compare preferential issue pricing with prevailing market prices. In this case, the revised warrant price of ₹84 is below the cited current price of ₹89.23. Bal Pharma’s final allotment terms and timing will still depend on the shareholder vote outcome and the completion of the stated process. The company has not, in the provided text, shared any additional financial performance numbers tied to this corrigendum beyond the size of the proposed raise.

What investors can track next

The immediate timeline is defined by the end of remote e-voting at 5:00 P.M. IST on August 8, 2026. Bal Pharma has said results will be announced at its registered office on or before August 11, 2026. Shareholders who are eligible based on the July 03, 2026 cut-off date can use NSDL’s remote e-voting framework to cast or revise votes within the window. The company’s disclosures also indicate the corrigendum is integral to the earlier notice, so investors may look for the final resolution text and outcome as declared with results. Any next steps on the preferential issue would logically follow the completion of the voting and the declaration of results, subject to the approvals sought through the postal ballot.

Conclusion

Bal Pharma’s corrigendum has revised the proposed convertible warrant issue price to ₹84 from ₹81, lifting the cited potential fund raise to ₹8.4 crore for an API plant in Karnataka. The company has kept the postal ballot e-voting window open through August 8, 2026 and enabled shareholders to modify votes to reflect the updated terms. It also offered a 48-hour period from its July 30 intimation for shareholders to submit comments on the corrigendum. The next confirmed milestone is the announcement of postal ballot results on or before August 11, 2026.